

Clinical Priorities Advisory Group

Wednesday 29 May 2019

10.30am - 4.30pm (at the latest)

(A break for lunch will be taken with the timing to be advised of on the day)

Venue: City Hall, The Queens Walk, London, SE1 2AA.

	Part I
Agenda item no.	1. Routine Business
1.1	Welcome and introductions Sir Nick Partridge, Chair
1.2	Apologies Sir Nick Partridge, Chair
1.3	Declarations of Interest for agenda items Sir Nick Partridge, Chair
1.4	Minutes from the previous meeting held on Tuesday 02 April 2019 Sir Nick Partridge, Chair
1.5	Public consultations – clinical policies and service specifications Sir Nick Partridge, Chair
1.6	Clinical commissioning publications agreed outside of CPAG Sir Nick Partridge, Chair
1.7	Matters Arising Sir Nick Partridge, Chair
	2. In Year Service Developments: Clinical Commissioning Policies
	Blood and Infection Programme of Care
2.1	1702: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV-1 in adults Mr James Palmer, Medical Director Specialised Services and Jacquie Kemp, Senior Manager – Trauma and Blood & Infection Programmes of Care
2.2	1742: Allogeneic haematopoietic stem cell transplant (HSCT) for primary immunodeficiencies (PID) (all ages) Mr James Palmer, Medical Director Specialised Services and Jacquie Kemp, Senior Manager – Trauma and Blood & Infection Programmes of Care
	3. Relative Priorisation: Clinical Commissioning Policies
	Blood and Infection Programme of Care

3.1	<p>1837: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid (bedaquiline in patients aged 6 years and over, and delamanid in patients aged 3 years) Mr James Palmer, Medical Director Specialised Services and Jacquie Kemp, Senior Manager – Trauma and Blood & Infection Programmes of Care</p>
Internal Medicine Programme of Care	
3.2	<p>1622: Lung volume reduction by surgery or endobronchial valve for severe emphysema in adults Mr James Palmer, Medical Director Specialised Services and Ursula People, Senior Manager – Internal Medicine Programme of Care</p>
3.3	<p>1714: Percutaneous Mitral Valve Leaflet Repair for primary degenerative mitral regurgitation (adults) Mr James Palmer, Medical Director Specialised Services and Ursula People, Senior Manager – Internal Medicine Programme of Care</p>
3.4	<p>1770: Percutaneous patent foramen ovale closure for the prevention of recurrent cerebral embolic stroke (adults aged 60 years or under) Mr James Palmer, Medical Director Specialised Services and Ursula People, Senior Manager – Internal Medicine Programme of Care</p>
Women and Children Programme of Care	
3.5	<p>1840: Sapropterin for phenylketonuria (all ages) Mr James Palmer, Medical Director Specialised Services and Anthony Prudhoe, Senior Manager – Women and Children Programme of Care</p>
3.6	<p>1623 / 1696: Chenodeoxycholic acid and cholic acid for inborn errors of bile metabolism (all ages) Mr James Palmer, Medical Director Specialised Services and Anthony Prudhoe, Senior Manager – Women and Children Programme of Care</p>
4. Close Meeting	
Part II - Members only	

